Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2018.271 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects with IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy including Dense Deposit Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2025.385 | A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2018.179 | A Phase 2 Study of Oraxol in Subjects with Cutaneous Angiosarcoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2021.563 | A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer |
Prof. YEO Winnie 楊明明教授 |
| 2003.030 | A Phase 2 Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer | Prof. Yeo Winnie |
| 2009.308 | A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy | Dr. WONG Raymond Siu Ming |
| 2003.191 | A Phase 2 Study of Fenretinide In Patients with Hormone Refractory Prostate Cancer | Prof. Mok S.K. Tony |
| 2024.592 | A Phase 2 Study Evaluating the Efficacy, Safety,Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) | Dr. LOONG Herbert Ho Fung |
| 2022.678 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in Participants with Chronic Hepatitis B Infection (STRIVE) | Prof. WONG Grace Lai Hung |
| 2022.676 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in HBeAg-negative Participants with Low Viral Burden of Chronic Hepatitis B Infection (THRIVE) | Prof. WONG Grace Lai Hung |
| 2022.634 | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus |
Prof. LUK Andrea On Yan 陸安欣 |
| 2019.022 | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2024.174 | A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic Non–Small-Cell Lung Cancer (mNSCLC) | Dr. LI Molly Siu Ching |
| 2022.571 | A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-02: Patients With Disease Progression After Receiving Systemic Treatment for Non-Small-Cell Lung Cancer (NSCLC) |
Dr. LI Molly Siu Ching 李兆澄醫生 |
| 2026.389 | A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion (MountainTap-5) | Dr. LOONG Herbert Ho Fung |
| 2022.182 | A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study |
Prof. NG Chi Fai 吳志輝 |
| 2024.659 | A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2021.113 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Dr. YIP Wai Man |
| 2021.112 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2023.268 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2026.231 | A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER | Prof. MOK Tony Shu Kam |
| 2022.285 | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) |
Prof. YEO Winnie 楊明明 |
| 2024.095 | A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors | Prof. MA Brigette Buig Yue |
| 2024.183 | A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression | Dr. LI Molly Siu Ching |
| 2024.313 | A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod Alone and in Combinations in Subjects with Chronic Hepatitis B Infection | Prof. WONG Grace Lai Hung |
| 2009.595 | A Phase 1B/2 Study of SCH 900105 in Combination with Gefitinib in Asian Subjects with Non-Small Cell Lung Cancer | Prof. Mok Tony |
| 2019.159 | A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOPHAGEAL JUNCTION |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.658 | A Phase 1b/2 Open-label Study of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either 5-Fluorouracil or Capecitabine Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction |
Dr. LOONG Herbert Ho Fung 龍浩鋒 醫生 |
| 2011.332 | A Phase 1b, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Hypoxia-Inducible Factor-1 alpha (HIF-1 alpha) mRNA Antagonist, Administered as a Weekly 2-Hour Intravenous Infusion (for 3 Weeks Per 4-Week Cycle) in Adul | Dr. CHAN Stephen Lam |
| 2024.253 | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol | Prof. CHAN Stephen Lam |
| 2024.248 | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) | Dr. LOONG Herbert Ho Fung |
| 2025.296 | A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNα-2a, Nivolumab or Durvalumab in Subjects with Chronic Hepatitis B |
Prof. WONG Grace Lai Hung Grace Wong |
| 2018.554 | A Phase 1b Open-Label, Proof of Concept Study to Evaluate the Safety and Efficacy of Novel Hepatitis B Virus (HBV) Combination Therapies in Chronic Hepatitis B (CHB) Subjects | Prof. WONG Grace Lai Hung |
| 2023.039 | A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime and Boost Vaccination Evaluation of Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2014.488 | A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients with HBeAg-Positive, Chronic Hepatitis B Virus Infection | Dr. CHAN Henry Lik Yuen |
| 2023.265 | A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung Lai Hung Wong |
| 2022.653 | A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection | Prof. WONG Grace Lai Hung |
| 2023.422 | A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients with Pulmonary Fibrosis or Thyroid Eye Disease | Prof. CHONG Kelvin Kam Lung |
| 2025.586 | A Phase 1/2a, Open-Label, Multiple-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects with Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) | Dr. BRELEN Marten |
| 2022.216 | A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106) |
Prof. CHAN Stephen Lam 陳林 |
| 2017.502 | A Phase 1/2, randomized, observer-blind, controlled, multi-center, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' respiratory syncytial virus (RSV) investigational vaccine based on the RSV viral proteins F, N and M2-1 encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A), when administered intramuscularly according to a 0, 1-month schedule to RSV-seropositive infants aged 12 to 23 months |
Prof. LEUNG Ting Fan 梁廷勳 |
| 2018.422 | A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2019.541 | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2022.651 | A Phase 1/2, Open-label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2026.036 | A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies | Dr. LI Molly Siu Ching |
| 2013.088 | A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy | Prof. YEO Winnie |
| 2025.366 | A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | Dr. LI Molly Siu Ching |
| 2019.381 | A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination with Pegylated Interferon Alpha-2a | Prof. WONG Vincent Wai Sun |
| 2019.518 | A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2022.261 | A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors | Dr. LOONG Herbert Ho Fung |
Page 272 of 289.